Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 15,126 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Terminated Not applicable Interventional Results available

Effect of Ejaculatory Abstinence on Semen Parameters in Male Factor Infertility Patients

NCT04206800
View directory record Official record
Conditions
Infertility, Male
Interventions
Ejaculatory abstinence less than 24 hours
Diagnostic Test
Lead sponsor
Boston IVF
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

NCT00056407
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years · Male only
Enrollment
8,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
297
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Infusion of CAP-1002 in Patients With COVID-19

NCT04623671
View directory record Official record
Conditions
Covid19
Interventions
CAP-1002, Placebo
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 4 Interventional

Narcotic vs. Non-narcotic Pain Study Protocol

NCT01974609
View directory record Official record
Conditions
Carpal Tunnel
Interventions
Narcotic, non-narcotic
Drug
Lead sponsor
Horizon Health Network
Other
Eligibility
18 Years to 90 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Sioux Falls, South Dakota • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study

NCT06274398
View directory record Official record
Conditions
Safety Issues
Interventions
TAF/EVG rectal insert, Matching placebo rectal insert
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

NCT00777595
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF 4226 pMDI, Placebo, Moxifloxacin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 23, 2026, 5:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

NCT01683071
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

E-cigarette Nicotine Study

NCT04709471
View directory record Official record
Conditions
Nicotine Dependence, Electronic Cigarette Use, Cigarette Smoking
Interventions
Nicotine, Juul e-cigarette, Reduction
Drug · Device · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-935 Multiple Rising Dose Study in Healthy Participants

NCT02539134
View directory record Official record
Conditions
Epilepsy
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers

NCT02202187
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

NCT04740931
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)

NCT04203537
View directory record Official record
Conditions
Postsurgical Pain
Interventions
CA-008, Placebo
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 80 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Pasadena, California • Carrollton, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

NCT06810245
View directory record Official record
Conditions
Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Relief RAL™: A Study Assessing the Impact of Health and Wellness Products on Pain Relief and Related Health Outcomes

NCT07262775
View directory record Official record
Conditions
Pain Interference
Interventions
Pain Relief Supplement Product Placebo Control, Pain Relief Supplement Active Product 1
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Terminated Phase 4 Interventional Results available

Double-Blind Placebo-Controlled CIN Trial

NCT02467075
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Iopamidol 300 (Contrast), Placebo (Normal Saline)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 23, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

NCT03330457
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (bolus), Betrixaban 80 mg PO QD, Andexanet alfa (infusion IV)
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

NCT01796301
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romozosumab, Teriparatide
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Gainesville, Georgia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

NCT05822830
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 23, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

The Medically Tailored Groceries and Mental Health Study

NCT07779707
View directory record Official record
Conditions
Depression / Major Depressive Disorder, Food Insecurity
Interventions
Medically Tailored, Home-delivered Groceries, Active Comparison Group: Monthly Grocery Gift Card
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Terminated Phase 4 Interventional

Comparison of Straumann BoneCeramic vs. Allograft Bone in Extraction Sockets

NCT00782236
View directory record Official record
Conditions
Tooth Loss
Interventions
Bone Graft Material
Device
Lead sponsor
Institut Straumann AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Yardley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 23, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Study of DONQ52 in Active Celiac Disease

NCT07239336
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52
Drug · Dietary Supplement
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
58
States / cities
Anniston, Alabama • Homewood, Alabama • Mobile, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 5:50 AM EDT